Lexicon Pharma (LXRX) Tops Q1 EPS by 5c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.30 +2.22%
Revenue Growth %: -86.1%
Financial Fact:
Interest expense: -1.65M
Today's EPS Names:
OVLY, UTMD, AMBZ, More
Revenue Growth %: -86.1%
Financial Fact:
Interest expense: -1.65M
Today's EPS Names:
OVLY, UTMD, AMBZ, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.07), $0.05 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $1.26 million versus the consensus estimate of $2.82 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SLM (SLM) Misses Q2 EPS by 16c; offers guidance
- Utah Medical Products (UTMD) Tops Q2 EPS by 84c
- Oak Valley Bancorp (OVLY) Tops Q2 EPS by 61c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
